ArticleInternational urology and nephrology2026
Functional outcomes and retreatment rates after iTIND implantation in a real-world Italian multicenter cohort: the importance of patient selection.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a ChatGPT-based assistant in multidisciplinary team discussions in oncological urology: the UroMDT Advisor study.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesLower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO) are common in aging men and impair quality of life. The temporary implantable nitinol device (iTIND) is a minimally invasive surgical treatment intended to improve symptoms while preserving sexual and ejaculatory function. We assessed functional outcomes, retreatment rates, and predictors of retreatment after iTIND implantation in a real-world Italian multicenter cohort.
methodsWe retrospectively analyzed prospectively collected data from 138 consecutive patients treated with iTIND at seven Italian institutions between January 2022 and May 2025. Follow-up was updated in March 2026 through outpatient visits or structured telephone interviews. Outcomes included IPSS, QoL, Qmax, PVR, IIEF-5, ejaculation preservation, pharmacological and surgical retreatment. Predictors of retreatment were evaluated using Cox regression and Kaplan-Meier analyses.
resultsMedian age was 52 years and median prostate volume was 30 mL. All procedures were completed successfully. QoL, IPSS, Qmax, and PVR significantly improved versus baseline at both follow-ups (adjusted p < 0.001). Between follow-ups, only Qmax slightly declined (adjusted p = 0.017), while other outcomes remained stable. Erectile function was unchanged, and antegrade ejaculation was mostly preserved. Adverse events were mild and self-limited. At 1 and 2 years, pharmacological retreatment rates were 21.7% and 37.7%, while surgical retreatment rates were 11.6% and 16.7%. Higher baseline IPSS, lower Qmax, and worse QoL predicted surgical retreatment.
conclusionsiTIND provides meaningful symptom improvement with sexual function preservation, but retreatment rates are clinically relevant. Careful patient selection is essential.
Indexed as
Identifiers
42570198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.